# Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

> **NCT04993625** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Jeong Eon Lee** · enrollment: 178 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT04993625
- **Lead sponsor:** Jeong Eon Lee
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-27
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2024-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993625, "Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04993625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*